| 20.09 13:55 | dpa-AFX: AbbVie: CHMP Adopts Positive Opinion For Mirvetuximab Soravtansine |
| 20.09 13:34 | dpa-AFX: *ABBVIE GETS POSITIVE CHMP OPINION FOR MIRVETUXIMAB SORAVTANSINE FOR THE TREATMENT OF ADULT OVARIAN CANCER |
| 10.09 13:08 | dpa-AFX: AbbVie Says Health Canada Approves CONSTELLA To Treat Functional Constipation In Pediatric Patients |
| 10.09 13:02 | dpa-AFX: *HEALTH CANADA APPROVES ABBVIE'S CONSTELLA FOR THE TREATMENT OF FUNCTIONAL CONSTIPATION IN PEDIATRIC PATIENTS |
| 06.09 16:54 | dpa-AFX: *ABBVIE (ABBV) DECLARES QUARTERLY DIVIDEND OF $ 1.55, RECORD DATE 10/15/2024 |
| 06.09 16:18 | dpa-AFX: *ABBVIE DECLARES QUARTERLY CASH DIVIDEND OF $1.55/SHR, PAYABLE NOV. 15, RECORD OCT. 15 |
| 04.09 14:19 | dpa-AFX: AbbVie: CDA Issues Positive Reimbursement Recommendation For VRAYLAR In Treatment Of Schizophrenia |
| 04.09 14:03 | dpa-AFX: *ABBVIE'S VRAYLAR GETS POSITIVE REIMBURSEMENT RECOMMENDATION IN CANADA FOR SCHIZOPHRENIA TREATMENT |
| 20.08 02:59 | dpa-AFX: AbbVie's Tepkinly Gets Conditional EU Approval For Relapsed Or Refractory Follicular Lymphoma |
| 16.08 10:31 | US-Regierung/Pharmakonzerne einigen sich auf niedrigere Medikamentenpreise |
| 15.08 16:15 | dpa-AFX: AbbVie Says Ontario, Quebec To Reimburse Epkinly Treatment Cost For Diffuse Large B Cell Lymphoma |
| 15.08 15:16 | dpa-AFX: *ABBVIE REPORTS ONTARIO&QUEBEC TO REIMBURSE EPCORITAMAB FOR DIFFUSE LARGE B-CELL LYMPHOMA UNDER NEW EARLY ACCESS PROCESS |
| 01.08 15:41 | dpa-AFX: AbbVie Completes Acquisition Of Cerevel; Reaffirms Full-year Adj. EPS Guidance Range |
| 01.08 14:29 | dpa-AFX: *ABBVIE REAFFIRMS FY ADJ. EPS GUIDANCE IN $10.71-$10.91 RANGE |
| 01.08 14:28 | dpa-AFX: *ABBVIE STILL EXPECTS Q3 ADJ. EPS TO BE $2.92-$2.96 |
| 01.08 14:26 | dpa-AFX: *ABBVIE CLOSES ACQUISITION OF CEREVEL THERAPEUTICS; REAFFIRMS 2024 ADJ. EPS GUIDANCE |
| 29.07 12:17 | dpa-AFX: *DZ BANK HEBT FV FÜR ABBVIE AUF 204 (188) USD - 'KAUFEN' |
| 29.07 12:17 | dpa-AFX: *DZ BANK RAISES FV FÜR ABBVIE TO 204 (188) USD - 'BUY' |
| 26.07 08:46 | dpa-AFX: European Commission Approves AbbVie's Skyrizi To Treat Ulcerative Colitis |
| 26.07 08:05 | dpa-AFX: *ABBVIE : EC OKS SKYRIZI FOR TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS |
|
|
